Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2014-10-22 M&A Activity
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
M&A Activity Classification · 99% confidence The document is a press release dated October 22, 2014, announcing an exclusive licensing and commercialization agreement between Lexicon and Ipsen regarding the drug telotristat etiprate. It details financial terms (upfront payment, milestones, royalties), clinical trial status (Phase 3), and includes forward-looking statements and contact information. This type of announcement, detailing a significant business transaction (licensing/partnership) and associated financial structure, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure without a better fit. However, since it explicitly details the financial structure of the deal (upfront payments, milestones, royalties), it strongly aligns with 'Capital/Financing Update' (CAP), which covers fundraising and capital structure changes, often including major partnership economics. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the focus on the financial structure of the deal, CAP is the most appropriate specific category.
2014-10-22 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 99% confidence The document is a press release dated October 22, 2014, announcing a licensing and commercialization agreement between Lexicon and Ipsen regarding the drug telotristat etiprate. It details financial terms (potential payments and royalties) and clinical development plans. This type of announcement, which details a significant business transaction, partnership, or financing event, aligns best with the 'Capital/Financing Update' (CAP) category, as it involves a major financial deal structure, or potentially 'Regulatory Filings' (RNS) if it were a general disclosure. However, given the specific focus on a licensing deal structure involving upfront payments, milestones, and royalties, 'CAP' is a strong fit, although 'RNS' is often used for press releases announcing material events. Since the definitions do not explicitly cover 'Partnership Announcement' or 'Press Release', and the content is heavily focused on the financial structure of the deal, I will evaluate against the closest fit. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a material business event announcement. In many databases, major licensing deals are classified under financing/corporate actions. Given the options, and since it's a press release announcing a major financial agreement, 'CAP' (Capital/Financing Update) is plausible, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for a non-standard press release. Since the deal involves significant financial components (payments, royalties), I lean towards CAP, but RNS is the general catch-all for press releases. Let's re-examine the definitions. None perfectly match 'Partnership Announcement'. Since it involves significant financial consideration and structuring, CAP is the most specific fit among the financial/corporate action codes. However, if this were a mandatory filing, it would likely be an RNS. Given the structure of the text (a formal press release announcing a strategic business transaction), RNS is the most appropriate general classification for non-standard regulatory disclosures that aren't explicitly defined elsewhere, especially since it's not a core financial report or management change.
2014-10-22 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated October 10, 2014, announcing positive results from a Phase III clinical study for a drug (Decapeptyl®). It details efficacy data (testosterone and PSA levels) and safety profiles, and mentions that Ipsen has applied for a label update based on these results. This content is characteristic of a company communicating significant operational or clinical development news to the public and investors, often preceding a formal financial filing. It is not a full Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a specific financial filing like an Earnings Release (ER) which focuses on P&L/Balance Sheet figures. Since it is a detailed announcement of clinical trial results and subsequent regulatory application, it best fits the category for general corporate news or investor-focused material. Given the detailed nature of the results presentation, it is more substantial than a simple 'Report Publication Announcement' (RPA). It aligns closely with an Investor Presentation (IP) in terms of content depth, but it is formatted as a press release. In the absence of a specific 'Clinical Trial Results Announcement' category, and considering it provides detailed strategic and scientific information aimed at investors, 'Investor Presentation' (IP) is the closest fit for substantive, non-financial performance updates. However, if we strictly adhere to the provided definitions, this is a press release announcing scientific/development progress. Since it is a detailed announcement of results and strategy updates, 'Investor Presentation' (IP) is the most appropriate classification among the choices for substantive, non-periodic financial updates.
2014-10-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated October 10, 2014, announcing positive results from a Phase III clinical study for the drug Décapeptyl® (triptorelin pamoate) in prostate cancer patients. It details efficacy data (testosterone control, PSA reduction) and mentions the presentation of these results at a European Association of Urology meeting. This type of announcement, focusing on clinical trial outcomes and scientific data presentation, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is a detailed announcement of scientific/clinical findings intended for investors and stakeholders, 'Investor Presentation' (IP) is the most fitting category, as it often overlaps with detailed press releases about clinical milestones, even if it's not a formal slide deck. It is not a formal regulatory filing like 10-K or IR, nor is it a management discussion (MDA) of periodic financial results. It is a specific announcement of scientific progress. FY 2014
2014-10-10 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release dated October 10, 2014, announcing the appointment of a new Executive Vice President, Chief Financial Officer (Aymeric Le Chatelier). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2014-10-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated October 10, 2014, announcing the appointment of Aymeric Le Chatelier as Executive Vice President in charge of Finance, effective November 3, 2014. This content directly relates to a change in senior management/board composition. Reviewing the definitions, the category 'Board/Management Information (Code: MANG)' is defined as 'Announcement of changes in the company's board of directors or senior management.' This perfectly matches the document's content. It is not an earnings release, a full annual report, or a proxy statement.
2014-10-10 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.